Q-omics provides the consensus-scored TTC7A profile across patient tissues and cancer cell-line models. TTC7A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TTC7A is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, TTC7A RNA expression shows 19,957 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KIRP, and UVM as cancer lineages where TTC7A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC7A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC7A survival associations across molecular data types. TTC7A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC7A RNA expression–survival associations across cancer types. High TTC7A expression shows unfavorable associations in LGG, OV, ACC and LIHC, but favorable associations in KIRC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TTC7A RNA expression.
This table summarizes TTC7A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for TTC7A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC7A shows lower tumor expression in KICH and LUSC and higher tumor expression in KIRP, KIRC, LIHC and HNSC. The KIRP box plot shows higher TTC7A RNA expression in tumor versus normal tissue (log2 FC = +0.939, t-test p < 0.001).
This table shows molecular features associated with TTC7A in patient tissues and cancer cell lines. In patient samples, TTC7A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC7A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
